Global Spatial Genomics & Transcriptomics Market: Introduction
Spatial genomics & transcriptomics enables researchers to not only see what is in a cell but how cells are organized in relation to one another, offering invaluable insights into understanding a disease by using the data that was earlier beyond the reach of modern methods. Spatial genomics & transcriptomics incorporates the exploration and assortment of transcriptomes. It has diverse applications, primarily in molecular genetics. The global spatial genomics & transcriptomics market is witnessing a lot of instances of new product launches. For example, Trio RNA-Seq launched by NuGEN Technologies, Inc. is particularly suitable for use in low-abundance transcript applications, as it offers an extremely sensitive whole transcriptomics solution. This innovation embodies three powerful technologies for performing high-sensitivity ribonucleic acid (RNA) analysis: single-primer isothermal amplification (SPIA), DimerFree, and AnyDeplete.
Global Spatial Genomics & Transcriptomics Market: Competition Landscape
Key players operating in the global spatial genomics & transcriptomics market are focusing on mergers and acquisitions. For instance, in December 2018, 10X Genomics acquired Spatial Transcriptomics, a pioneer in the emerging field of spatial genomics. Spatial Transcriptomics offers a technology designed to allow RNA sequencing to perform in the 2D technology. In August 2018, 10X Genomics acquired Epinomics, a pioneer in the growing space of epigenetics. The acquisition would provide 10X Genomics with the ATAC-seq technology and fundamental IP to accelerate discoveries and conduct further research in epigenomics.
Identify the key factors that will drive your company’s growth. Request a brochure of this report here
Founded in 2012, 10X Genomics is headquartered in California, the U.S. The company develops integrated systems and solutions for genome sequencing, exome sequencing, and single-cell transcriptomics. 10X Genomics, Inc. was formerly known as 10X Technologies, Inc. and it changed its name to 10X Genomics, Inc. in March 2015. The company offers chromium single-cell gene expression solutions, chromium single-cell immune profiling solutions, chromium single-cell CNV solutions, chromium single-cell ATAC solutions, chromium genome solutions, chromium exome solutions, and chromium de novo assembly solutions.
Established in 2000, Illumina, Inc. is headquartered in California, the U.S. The company is a global life science company engaged in the development and commercialization of genetic analysis solutions covering the areas such as sequencing, genotyping, and expression. The company operates its business through two major segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc. (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of Illumina, Inc.’s core operations. Core Illumina's products and services serve customers in research, clinical, and applied sectors and enable the adoption of a wide range of genomic solutions. The company provides whole-genome sequencing, genotyping, NIPT, and support services. The company's technology platforms support the scale of experimentation required for population-scale studies, genome-wide discovery, target selection, and validation studies.
Dovetail Genomics LLC
Founded in 2013, Dovetail Genomics LLC is headquartered in California, the U.S. The company’s business line includes providing commercial, physical and biological research and development services. The company is involved in de novo assembly, structural variation, microbiome analysis, cancer research, phasing analysis, and comprehensive view of genomes. In 2018, the company introduced its first commercial service for analysis of human genomes.
Expanding operations in future? To get the perfect launch ask for a custom report here
Global Spatial Genomics & Transcriptomics Market – Dynamics
Drug discovery and disease identification a key driver
Increasing awareness about disease management and drug discovery drives the global spatial genomics & transcriptomics market. Disease management and drug discovery are the most rapidly expanding application segments of the market. The rise in genome knowledge has led to increased research in several, rare, genetic and oncology diseases. Also, the increasing demand from diagnostics in neurology and immunology as well as other areas of biology has been significantly driving the market. Personalized medicine and companion diagnostics are significant add-on part responsible for growth of the global spatial genomics & transcriptomics market. According to a magazine called Labtimes, over 700,000 genetic tests are performed in Europe every year and over 30 million people suffer from some form of a genetic disorder. Spatial genomics technology bridges microscopy and RNA sequencing to generate complete transcriptome data from a single intact tissue sample and utilizes standard instrumentation for sequencing already present in most labs, allowing for barrier-free adoption.
Increased investments in genomics
With increasing investment in spatial genomics & transcriptomics along with expanding supporting growth from investors are expected to offer the greatest market attractiveness in terms of revenue. Certain countries do have challenging entry barriers in terms of political and legal framework clearance. However, with increasing awareness and adoption, the market penetration is expected to offset the entry barriers. Government funding and support and collaborative research with large pharmaceutical players are estimated to be significant drivers of this market in the near future. For instance, in January 2019, 10X Genomics received a combined funding of US$ 243 Mn, of which US$ 35 Mn was an extension of 10X Genomics Series-D financing.
Global Spatial Genomics & Transcriptomics Market – Segmentation
Based on the product & service, the global spatial genomics & transcriptomics market can be segmented into:
Based on application, the global spatial genomics & transcriptomics market can be divided into:
- Diagnostics & Disease Profiling
- Drug Discovery
Based on end-user, the global spatial genomics & transcriptomics market can be classified into:
- Government Institutes & Academic Centers
- Pharmaceutical & Biotechnology Companies
- Contract Research Organizations (CROs)
The report offers a comprehensive evaluation of the market. It does so via in-depth qualitative insights, historical data, and verifiable projections about market size. The projections featured in the report have been derived using proven research methodologies and assumptions. By doing so, the research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology, types, and applications.
The study is a source of reliable data on:
- Market segments and sub-segments
- Market trends and dynamics
- Supply and demand
- Market size
- Current trends/opportunities/challenges
- Competitive landscape
- Technological breakthroughs
- Value chain and stakeholder analysis
The regional analysis covers:
- North America (U.S. and Canada)
- Latin America (Mexico, Brazil, Peru, Chile, and others)
- Western Europe (Germany, U.K., France, Spain, Italy, Nordic countries, Belgium, Netherlands, and Luxembourg)
- Eastern Europe (Poland and Russia)
- Asia Pacific (China, India, Japan, ASEAN, Australia, and New Zealand)
- Middle East and Africa (GCC, Southern Africa, and North Africa)
The report has been compiled through extensive primary research (through interviews, surveys, and observations of seasoned analysts) and secondary research (which entails reputable paid sources, trade journals, and industry body databases). The report also features a complete qualitative and quantitative assessment by analyzing data gathered from industry analysts and market participants across key points in the industry’s value chain.
A separate analysis of prevailing trends in the parent market, macro- and micro-economic indicators, and regulations and mandates is included under the purview of the study. By doing so, the report projects the attractiveness of each major segment over the forecast period.
Highlights of the report:
- A complete backdrop analysis, which includes an assessment of the parent market
- Important changes in market dynamics
- Market segmentation up to the second or third level
- Historical, current, and projected size of the market from the standpoint of both value and volume
- Reporting and evaluation of recent industry developments
- Market shares and strategies of key players
- Emerging niche segments and regional markets
- An objective assessment of the trajectory of the market
- Recommendations to companies for strengthening their foothold in the market
Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.